Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 13/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.31 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.31 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13475348 | 0.81 | ADK (0.41) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL13060279 | 0.81 | BLM (0.54) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL3797209 | 0.78 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1 | |
| SCHEMBL887895 | 0.76 | MEN1 (0.39) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL10228146 | 0.73 | KMT2A (0.34) | MEN1ALDH1A1KMT2AHSP90AA1 | |
| SCHEMBL10389964 | 0.69 | DYRK3 (0.56) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL9583145 | 0.69 | MEN1 (0.62) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL3804738 | 0.69 | HSP90AA1 (0.54) | ALDH1A1LMNAHSP90AA1HSP90AB1 | |
| SCHEMBL13071348 | 0.69 | BLM (0.47) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL13379601 | 0.68 | ALDH1A1 (0.48) | MEN1ALDH1A1LMNACYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | MEN1 2875/4885ALDH1A1 1889/4885LMNA 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.